During the mucormycosis crisis in India, Gilead supplied over 1 million vials of AmBisome® to help patients get the treatment they needed.6
Gilead and the WHO are now working together to expand access to diagnosis and treatments for visceral leishmaniasis in key endemic countries, such as Brazil, India and Ethiopia.6,7
As the carefully selected treatment for over 2 million patients with life-threatening IFIs,2 AmBisome® has crossed oceans to provide hope for so many families across the world.
Take a look at some of the most important milestones for AmBisome® over the past 30 years , from the first licence in Ireland in 1990 to the production of over 100 million vials today.
In the fight against life-threatening IFIs, Gilead are dedicated to ensuring a consistently high-quality supply of AmBisome®. Today, the new La Verne facility can produce up to 50,000 vials in one batch, corresponding to over 650 kg of AmBisome®, ensuring patients can continue to benefit from AmBisome® across the world.
Date of preparation: April 2022. Job code: IHQ-AMB-0432.